No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic...

Area of Science:

• Immunology
• Rheumatology
• Cardiology

Background:

• Cardiovascular morbidity is a leading cause of death in Systemic Lupus Erythematosus (SLE) patients.
• Previous research suggested a link between low mannose-binding lectin (MBL) levels and cardiovascular disease (CVD) in SLE.
• Large-scale studies on MBL plasma concentrations and CVD risk in SLE are limited.

Purpose of the Study:

• To investigate the association between MBL plasma concentrations and the occurrence of CVD in a large cohort of SLE patients.
• To determine if MBL deficiency is an independent risk factor for CVD in SLE.
• To identify key risk factors for CVD in SLE patients.

Main Methods:

• Plasma MBL levels were measured using ELISA in 373 SLE patients from the Swiss SLE Cohort Study.
• Five distinct cardiovascular organ manifestations were documented for each patient.
• Statistical analysis was performed to assess the association between MBL levels, CVD, and traditional CV risk factors, including antiphospholipid serology (APL+).

Main Results:

• No significant increase in CVD frequency was observed in patients with MBL deficiency (defined as <500 ng/ml or <1000 ng/ml).
• After adjusting for traditional CV risk factors, age, hypertension, disease duration, and APL+ remained significantly associated with CVD.
• The study did not confirm previous findings suggesting MBL deficiency as a risk factor for CVD in SLE.

Conclusions:

• Low MBL plasma concentrations are not associated with an increased risk of CVD in this large SLE cohort.
• Traditional cardiovascular risk factors and antiphospholipid serology are significant predictors of CVD in SLE patients.
• Further research may be needed to fully elucidate the role of MBL in SLE pathogenesis and cardiovascular complications.